System Labs Review: It Tells You the Truth About FDA Status — Now Ask What the Evidence Actually Shows

What Is System Labs?

System Labs, operating as SYSTEM LABORATORIES, INC., is a telehealth platform selling compounded peptides on monthly subscription. Its catalogue spans compounded GLP-1/GIP for weight loss, NAD+ injections, sermorelin (injectable or oral dissolving tablet), glutathione, MIC+B12 lipotropic injections and a GHK-Cu topical cream. You complete an intake, a licensed clinician reviews it, and medication ships from US pharmacies with injection supplies included and two-day temperature-controlled delivery.

The pricing is published, which is welcome, and structured around a heavy first-month discount. Compounded GLP-1/GIP is $99 for month one then $179; NAD+ is $89 then $149; sermorelin is $109 then $219. Read those pairs carefully — the step-ups are 81%, 67% and 101% respectively. Plans can be paused or cancelled at any time, and each includes injection supplies, temperature-controlled shipping and 20% off a blood test.

Credit where it is due on disclosure. System Labs carries what is genuinely one of the more honest regulatory statements in this market: 'The peptide medications and therapies offered have not been approved by the FDA. The FDA has not evaluated statements regarding benefits of these therapies. These products are not intended to diagnose, treat, cure, or prevent any disease. Individual results may vary. Use of compounded medications involves known and unknown risks that should be discussed with your clinician.' That last clause in particular is something most competitors would never write.

The problem is what sits underneath the disclosure. The company launched in April 2026, so it is roughly four months old at the time of this review, and we could find no BBB profile and no Trustpilot record — there is simply nothing independent to check. And the longevity products that make up most of the menu rest on much weaker evidence than the marketing language implies, which is the substance of this review.

Products & Pricing

Prices are System Labs' published rates as at 6 August 2026. The single most important thing here is the size of the month-two step: GLP-1 goes from $99 to $179 (+81%), NAD+ from $89 to $149 (+67%) and sermorelin from $109 to $219 (+101%). The first-month figure is a promotional rate, not the price of the programme. Compare competitors against the ongoing number — at $179/mo for compounded GLP-1, System Labs is roughly double what several providers we review charge for the same regulatory category.

Regulatory Status and What the Evidence Actually Shows

Everything System Labs sells is compounded and none of it is FDA-approved. The company says so clearly and repeatedly, which is more than many competitors do, and it explicitly acknowledges that compounded medications carry 'known and unknown risks.' Take that statement seriously rather than treating it as boilerplate — it is accurate.

The evidence position varies enormously across the catalogue, and the marketing does not distinguish between them. Compounded GLP-1/GIP is the item with the strongest underlying pharmacology, because the branded GLP-1 medicines it imitates have large positive trials behind them — though no compounded version has itself been trialled, and the compounded preparation is not equivalent to the approved drug.

Sermorelin is a different matter. It is a growth hormone-releasing hormone analogue that was historically approved only as a diagnostic agent for growth hormone deficiency in children, under the brand Geref, which was discontinued. It has no FDA approval for adult body composition, sleep, recovery or longevity, and the human outcome evidence for those uses is thin. System Labs advertises 'lean muscle, deeper sleep, real recovery' and states that body composition changes 'typically become more apparent after 6 to 12 weeks.' Those are specific expectations set against evidence that does not really support them.

Injectable NAD+ is weaker still. Most published human research in this area concerns oral precursors such as nicotinamide riboside and NMN, and even there the findings are largely biomarker changes rather than demonstrated improvements in energy, cognition or ageing. Controlled outcome trials of injected NAD+ in healthy adults are essentially absent. 'More energy, sharper thinking, slower aging' is marketing language, not a clinical finding.

Glutathione injections and MIC+B12 lipotropic shots both lack good evidence for their marketed uses — MIC+B12 has repeatedly failed to show meaningful weight-loss benefit in the absence of deficiency, and injectable glutathione has drawn regulatory warnings elsewhere in the world when sold for skin lightening. GHK-Cu cream is a cosmetic copper peptide with some small-scale skin research behind it and correspondingly modest claims.

The Consultation Process

Eligibility

• •Eligibility is determined by a licensed clinician from your online intake. No specific criteria are published on the landers we reviewed, and no lab work is required as a condition of treatment.
• •States served are not published. Confirm availability before subscribing.
• •GLP-1 medicines are contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, and must not be used in pregnancy or while trying to conceive. Clinician judgement is required with a history of pancreatitis, gallbladder disease, gastroparesis or diabetic retinopathy. Common side effects are gastrointestinal.
• •Growth hormone-releasing agents such as sermorelin should not be used by anyone with an active malignancy, and warrant real caution in anyone with a history of cancer, because the growth hormone/IGF-1 axis is implicated in cell proliferation. They can also affect glucose tolerance. This is a conversation to have with a clinician who knows your history — not a box to tick on an intake form.
• •Anyone with diabetes or impaired glucose regulation should be cautious with growth-hormone-axis therapies, which can worsen insulin resistance.
• •Compounded injectables carry infection and sterility risk inherent to any injection, and — as System Labs itself states — the additional 'known and unknown risks' of preparations that have not been through FDA review for quality.
• •None of these products should be understood as treatment for a diagnosed condition. If you have fatigue, poor sleep, low mood or unexplained body composition change, those warrant a proper diagnostic workup — thyroid, iron, B12, sleep apnoea, depression, testosterone — before a peptide subscription.

Clinicians, Lab Testing & Pharmacy

Shipping & Support Services

Two-day temperature-controlled shipping is included in every plan, along with injection supplies. For peptide products this is the right standard — cold-chain handling genuinely matters — and bundling supplies rather than charging separately is better practice than several competitors.

• •Unusually complete and honest FDA disclosure, including acknowledgement of unknown risks
• •Published pricing on each product lander
• •Injection supplies included in every plan
• •Two-day temperature-controlled shipping included
• •20% off a blood test bundled with plans
• •Pause or cancel at any time
• •Both injectable and oral dissolving tablet options for sermorelin
• •Broad menu across weight loss, longevity and topical peptides

Fees, Cancellation & Refunds

Insurance & HSA/FSA

Pros & Cons

Who System Labs May Be Best For

• •People who specifically want compounded peptide therapy, understand the evidence is limited, and want a provider that says so plainly
• •Anyone who values included supplies and proper cold-chain shipping over the lowest headline price
• •Patients who want to try a peptide protocol without an annual commitment, given the cancel-anytime terms

Limitations

• •The evidence gap is the heart of this review, and it is not a technicality. System Labs' own disclaimer says its products are 'not intended to diagnose, treat, cure, or prevent any disease' — and that is legally accurate. But the landers simultaneously promise 'more energy, sharper thinking, slower aging' from NAD+ and 'lean muscle, deeper sleep, real recovery' from sermorelin, with timelines attached. Those two things cannot both be doing honest work. If a product genuinely is not intended to treat anything, it should not carry an expected onset of benefit.
• •For NAD+ specifically, the human research base is much thinner than the category's popularity suggests. Most controlled data concerns oral precursors and shows biomarker shifts rather than demonstrated improvements in energy, cognition or ageing outcomes. Injected NAD+ in healthy adults has almost no controlled outcome evidence at all. At $149/mo ongoing, that is a substantial subscription for an unproven benefit.
• •Sermorelin carries an additional caution rather than merely an evidence gap. It acts on the growth hormone/IGF-1 axis, which is implicated in cell proliferation, so it warrants real care in anyone with a cancer history and can affect glucose tolerance. Prescribing it without required baseline bloods, from a questionnaire, is the part of System Labs' model we would push back on hardest — the included blood-test discount is an upsell, not a safeguard.
• •The month-two pricing structure is aggressive even by this market's standards. Doubling the price of sermorelin after the introductory month means the number you decided on is not the number you pay from month two onward, and the cancel-anytime policy only helps if you notice. Diarise the renewal.
• •Four months of trading with no BBB profile and no review corpus means there is nothing to verify. That is not an accusation — every company starts somewhere — but combined with cash-pay subscriptions, no published refund policy and products whose benefit is hard to assess subjectively, it concentrates a lot of unverifiable trust in a very new counterparty.
• •In fairness, System Labs does several things better than its competitors. Bundling supplies and temperature-controlled shipping, publishing prices, imposing no minimum term, and writing an FDA disclaimer that actually admits unknown risks are all above the norm here. If the catalogue were built on better-evidenced products, this would be a considerably higher rating.

Alternatives to Consider

Frequently Asked Questions

Our Verdict

System Labs is the rare compounded-peptide seller that does not hide behind vague language. Its FDA disclosure is complete, prominent and unusually candid — it says the products are unapproved, that the FDA has not evaluated the benefit claims, that they are not intended to treat any disease, and that compounding carries known and unknown risks. Published pricing, included injection supplies, proper two-day cold-chain shipping and genuine cancel-anytime terms all sit above this market's average.

What it sells is the problem. Outside the GLP-1, this is a catalogue of products whose marketed benefits are not established: injectable NAD+ has essentially no controlled human outcome evidence, sermorelin has no approval or good data for adult body composition and sleep, and MIC+B12 has repeatedly failed to demonstrate weight-loss benefit. Advertising 'sharper thinking' and 'body composition changes after 6 to 12 weeks' beside a disclaimer that the products treat nothing is a contradiction the reader has to resolve, and the honest resolution is that you are buying a hypothesis.

The commercial structure compounds it. First-month pricing that rises by up to 101% in month two means the figure that persuaded you is not the figure you pay, and at $179/mo ongoing the GLP-1 is roughly double what several established providers charge for the same regulatory category. With four months of trading, no BBB profile, no review corpus and no published refund policy, there is nothing to check and little to recover.

We rate System Labs 2.6 out of 5. Honest about regulation, thin on evidence, expensive from month two, and too new to verify. If you want a GLP-1, CoreAge Rx at $99/mo or CallonDoc at $89/mo cost less with real track records. If your actual concern is fatigue, poor sleep or body composition, get a proper workup first — Hone Health's 50+ biomarker panel is a better use of the same money than a peptide subscription aimed at symptoms nobody has measured.

This review is informational only and is not medical advice. Compounded peptides are not FDA-approved and have not been evaluated for the benefits advertised. Speak to a licensed clinician about whether any of this is appropriate for you — particularly if you have a history of cancer or impaired glucose regulation — before starting, changing or stopping any treatment.